Alexander Everhart, PhD has been named a co-investigator on an R01 with Yale University and the University of Maryland that evaluates effects of the Inflation Reduction Act. The project will examine the impacts of the Inflation Reduction Act on older adults with type 1 diabetes and type 2 diabetes across the United States.
“It’s rare to have such a large change in the affordability of medicines like what happened with the Inflation Reduction Act, so we’re excited to dig into the data and see how that’s affected patients,” Everhart shared.
The project is titled “Insulin Affordability: Unpacking the Impact of the Inflation Reduction Act on Diabetes Outcomes and Equity in Medicare.” It looks across the United States, with respect to out-of-pocket payments for insulin, clinical outcomes associated with optimal treatment of diabetes, and racial and ethical disparities in diabetes care quality and outcomes.
“This is my first time serving as a co-investigator on an R01,” Everhart shares. “We somehow managed to get it funded on the first try, so I’m going to have wildly unrealistic expectations about getting grants going forward.”